3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Prostatic Neoplasms
9
Neoplasms
9
Lung Neoplasms
6
Endometrial Neoplasms
6
Breast Neoplasms
6
Stomach Neoplasms
4
Oropharyngeal Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Pathologic Complete Response
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Mouth Neoplasms
3
Leukemia, Myeloid, Acute
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Meningioma
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leiomyoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Carcinoma, Basal Cell
2
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Interventions
Gemcitabine
15
Cisplatin
15
pembrolizumab
9
Oxaliplatin
7
durvalumab
5
Leucovorin
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
Platinum
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
Trastuzumab
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Capecitabine
3
zanidatamab
2
fludarabine
2
Paclitaxel
2
Nivolumab
2
Folfox protocol
2
Docetaxel
2
Cyclophosphamide
2
Biopsy
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
pertuzumab
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Observation
×
1 year
×
Clear all
NCT06192719
2026-02-18
EULAT
Centre Paul Strauss
Recruiting
15,000 enrolled